Correlation between ApoE gene polymorphisms and the occurrence of urolithiasis
Biao Qian1, Liying Zheng2, Qinzhang Wang1
1Department of Urology, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, Xinjiang 832003, P.R. China.
Experimental and Therapeutic Medicine
|December 3, 2014
Summary
The apolipoprotein E (ApoE) gene E4 allele is linked to a higher risk of urolithiasis. This study found a significant association between ApoE gene polymorphisms and the occurrence of kidney stones.
Area of Science:
- Genetics
- Urology
- Biochemistry
Background:
- Apolipoprotein E (ApoE) plays a crucial role in lipid metabolism.
- Gene polymorphisms, particularly in ApoE, are implicated in various diseases.
- Urolithiasis and dyslipidemia are common health conditions with complex etiologies.
Purpose of the Study:
- To investigate the correlation between apolipoprotein E (ApoE) gene polymorphisms and urolithiasis.
- To explore the association between ApoE gene variants and dyslipidemia in a Uyghur population.
Main Methods:
- Case-control study involving 180 Uyghur individuals (90 urolithiasis patients, 90 healthy controls).
- Analysis of blood lipid profiles and urinary calculi composition.
- Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to determine ApoE genotypes (E3/3, E3/4, E4/4).
Main Results:
- The frequency of the ApoE E3/4 genotype was significantly higher in urolithiasis patients (64.4%) compared to controls (38.9%) (P<0.001).
- The E4 allele frequency was also significantly elevated in the patient group (P=0.025).
- No significant difference in blood lipid profiles was reported between groups in the abstract.
Conclusions:
- Apolipoprotein E (ApoE) gene polymorphisms are associated with the occurrence of urolithiasis.
- The ApoE E4 allele may represent a susceptibility factor for developing kidney stones.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
168
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
168
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
135
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
01:29Pharmacogenomics: Identification of New Drug Targets
104
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
01:11Genome-wide Association Studies-GWAS
17.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
17.2K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
83
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
83